Novus Biologicals

Novus Biologicals

Founded in 1996 by Karen Padgett, Novus Biologicals began as a specialized supplier of antibodies to university laboratories and has since expanded into a multi-site operation with headquarters in Centennial, Colorado and additional offices in Grand Rapids, Michigan, Charlevoix, Michigan, and Utrecht, Netherlands. The firm developed its business entirely outside the venture capital model, growing organically through revenue reinvestment—a structural rarity in the life sciences tools space where most competitors of scale are publicly traded or private equity-backed. Novus Biologicals positions itself as a product-centric organization rather than a service provider, manufacturing and distributing over 200,000 primary antibodies, recombinant proteins, ELISA kits, and small molecules for the biomedical research community. Its catalog companies include Novus Biologicals LLC, Bio-Techne's corporate umbrella following a 2014 acquisition, though the brand operates with significant operational independence. Known portfolio of research products includes antibodies targeting p53, TNF-alpha, and HIF-1 alpha—workhorse reagents that appear in thousands of peer-reviewed publications annually. The firm distributes to academic institutions, pharmaceutical R&D groups, and government labs across North America, Europe, and Asia-Pacific. Headcount estimates place the team between 50-200 employees across its four offices, with the Centennial and Grand Rapids locations handling North American distribution and product development. July 2014: Entered into a definitive agreement to be acquired by Techne Corporation (now Bio-Techne) for approximately $60 million in cash (per Techne Corporation press release, July 2014). The acquisition integrated Novus into Bio-Techne's broader life sciences platform while preserving the brand identity and product catalog. Adjacent corporate relationships within Bio-Techne include R&D Systems and Tocris Bioscience, creating a diversified reagent portfolio under shared ownership. Novus Biologicals' structural differentiator lies in its catalog breadth per employee and its early adoption of an e-commerce-first distribution model in the life sciences—a field still dominated by field-sales representative calling on individual labs when the firm launched in 1996. Its integration into Bio-Techne provides balance-sheet support typically absent from founder-led reagent companies, while maintaining a degree of autonomous brand operation that allows the Novus catalog to compete with both large incumbents like Abcam and community-driven platforms like Addgene.